Jounce Therapeutics, Inc. Common Stock
JNCE
JNCE was delisted on the 3rd of May, 2023.
102 hedge funds and large institutions have $99.5M invested in Jounce Therapeutics, Inc. Common Stock in 2022 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 29 increasing their positions, 35 reducing their positions, and 13 closing their positions.
170% more call options, than puts
Call options by funds: $437K | Put options by funds: $162K
8% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 13
0% more funds holding
Funds holding: 102 → 102 (0)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
17% less repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 35
23% less capital invested
Capital invested by funds: $129M → $99.5M (-$29.8M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OCA
Octagon Capital Advisors
New York
|
+$4.96M |
| 2 |
CAC
Cowen and Company
New York
|
+$2.85M |
| 3 |
RI
RTW Investments
New York
|
+$2.65M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$1.49M |
| 5 |
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Toronto,
Ontario, Canada
|
+$1.08M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SI
Sofinnova Investments
Menlo Park,
California
|
-$2.98M |
| 2 |
TGI
TRV GP II
Boston,
Massachusetts
|
-$2.74M |
| 3 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$2.02M |
| 4 |
ABG
Ally Bridge Group
New York
|
-$1.67M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.49M |
JNCE Hedge Fund Activity: Q3 2022 in Review
102 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in Jounce Therapeutics, Inc. Common Stock (JNCE) for Q3 2022, worth a combined $99.5M — down 23% from $129M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new JNCE positions and 13 closed out — a net gain of 1 holder — while 29 added to existing stakes and 35 trimmed.
The largest buyer was Octagon Capital Advisors, opening a new position worth an estimated $4.96M. The largest seller was Sofinnova Investments, exiting entirely with an estimated $2.98M sold.
- 102 institutional investors held Jounce Therapeutics, Inc. Common Stock (JNCE) as of Q3 2022, unchanged from Q2 2022.
- Funds reported $99.5M of Jounce Therapeutics, Inc. Common Stock stock for Q3 2022, down 23% quarter-over-quarter.
- 14 funds opened new Jounce Therapeutics, Inc. Common Stock positions in Q3 2022 and 13 closed out, a net change of +1 holder.
- The largest Jounce Therapeutics, Inc. Common Stock buyer in Q3 2022 was Octagon Capital Advisors, an estimated $4.96M added.
- The largest Jounce Therapeutics, Inc. Common Stock seller in Q3 2022 was Sofinnova Investments, an estimated $2.98M sold.
Based on aggregated 13F filings for Q3 2022.